Retrieved 22 January 2021.
The studies will evaluate the safety, tolerability, and immunogenicity of heterologous prime-boost sequential immunizations using INO-4800 and CoronaVac.
Retrieved 10 March 2021.
This means the process can be standardised and scaled up, making vaccine development faster than traditional methods of making vaccines.
It is marketed under the name.
Retrieved 22 March 2021.